TITLE

The patentability of medicinal inventions related to personalized medicine in Japan

AUTHOR(S)
Shimbo, Itsuki; Cobden, Andrew; Sumikura, Koichi
PUB. DATE
November 2005
SOURCE
Nature Biotechnology;Nov2005, Vol. 23 Issue 11, p1367
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on the several amendments of the examination guidelines for medicinal inventions in Japan. Possibility of obtaining a patent for a medicinal innovation by specifying the class of patients; Protection of the combinations of medicines and optimization of dosage and frequency of administration; Impact of the new patent guidance on pharmaceutical companies.
ACCESSION #
18750950

 

Related Articles

  • Whose Property Is It, Anyway?  // European Pharmaceutical Executive;May/Jun2006, p18 

    The article discusses the need for the pharmaceutical industry to change its attitude towards intellectual property to survive the changing climate of patent rights in Europe. It focuses on the issue of whether the possession of a single patent was sufficient grounds to bring someone else's...

  • Domestic Patents - Questions You Should Ask Your Patent Attorney. Pershes, Robert; Wagner, Louis // BioPharm International;Aug2005, Vol. 18 Issue 8, p10 

    Explores the steps in seeking and managing a patent for pharmaceutical products in the U.S. Assessment on the suitability of a drug discovery to be patented; Consideration of the free use provisions of the teachings and protection contained in the patent; Factor posing literal infringement of...

  • Pharmaceuticals and intellectual property rights: A political economy of the recent policy changes across the developing world and in Turkey. Vural, ─░pek Eren // Middle East Technical University Studies in Development;Dec2007, Vol. 34 Issue 2, p337 

    This paper explores the sources of the recent policy changes from weaker to stronger intellectual property regimes (IPRs) for pharmaceuticals across the developing world, and in Turkey. Analysing the policy change from a political economy approach, the paper argues that the increased structural...

  • Demystifying the Patent Reform Act and its Impact on Company IP Strategy. Gay, David A.; Gaede, William // BioPharm International;Jan2007, Vol. 20 Issue 1, p34 

    The article comments on the proposed Patent Reform Act of 2005 in the United States. The Act stems from reports by the Federal Trade Commission and the National Academies of Sciences which address a need to improve the efficiency and quality of the system. The article examines the impact of the...

  • A HARD PILL TO SWALLOW: DOES SCHERING V. GENEVA ENDANGER INNOVATION WITHIN THE PHARMACEUTICAL INDUSTRY? De La Rosa, Alfredo // Columbia Science & Technology Law Review;2008, Vol. 9, p37 

    Recently the Federal Circuit has adopted a sweeping new rule of inherent anticipation that essentially bars the patenting of metabolites and other biological degradations of chemical compounds. This new rule, adopted in Schering v. Geneva, could substantially affect both the willingness and the...

  • Pharma patents: India ranks second.  // Siliconindia;Sep2005, Vol. 9 Issue 8, p15 

    Reports on the increasing number of applications for patent of pharmaceutical products in India. Invention of critical life saving drugs by the pharmaceutical companies; Launch of drugs at a frenetic pace in Western countries; Attraction of international attention by the pharmaceutical firms...

  • Drill to widen patent domain.  // Telegraph (Calcutta, India);9/14/2015, p1 

    The aticle reports that the union cabinet will be considering a new policy on intellectual property rights (IPR) that will protect innovators by toughening patent rules and will make it easier for companies to file for patents. The new rules will not change the provisions prohibiting the patent...

  • Patent Cliff Reshaping Pharmaceutical Sector.  // Chain Drug Review;8/27/2012, Vol. 34 Issue 14, p113 

    The article focuses on the problem faced by the pharmaceutical industry in the U.S. due to expiry of patent protection of brand name drugs such as Pfizer Inc.'s Lipitor, which results in multi million-dollar loss in revenues to the company.

  • Introduction: An Overview of Intellectual Property. Brown, Frederick; Tai, June T. // BioPharm International;Aug2005, Vol. 18 Issue 8, p4 

    Discusses the intellectual property issues facing pharmaceutical companies in the U.S. Significance of a patent in providing an inventor with a temporary monopoly on an invention in exchange for full disclosure; Importance of copyright protection to biopharmaceutical companies seeking...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics